CMMB
Chemomab Therapeutics Ltd.
NASDAQ · Healthcare · Biotechnology · IL
$2.71
−4.24%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | — | — | — | 66.8K | 57.8K |
| Gross Profit | — | — | — | (66.8K) | (57.8K) |
| Operating Expenses | |||||
| R&D Expense | 4.1M | 5.8M | 11.3M | 18.4M | 17.0M |
| SG&A Expense | 3.8M | 3.7M | 3.4M | 7.1M | 11.6M |
| General & Admin Expense | 2.7M | 3.7M | 3.4M | 7.1M | 11.6M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 5.5K | — | — | — | — |
| Total Operating Expenses | 8.0M | 9.6M | 14.7M | 25.5M | 28.5M |
| Cost and Expenses | 8.0M | 9.6M | 14.7M | 25.5M | 28.5M |
| Operating Income (EBIT) | (8.0M) | (9.6M) | (14.7M) | (25.5M) | (28.5M) |
| Non-Operating | |||||
| Interest Income | 358.2K | 572.0K | 794.0K | 1.2M | 351.6K |
| Interest Expense | — | — | — | — | 353.0K |
| Net Interest Income | 358.2K | 572.0K | 794.0K | 1.2M | (1.4K) |
| Other Non-Op Income/Expense | 357.9K | 572.0K | 794.0K | 1.2M | 353.0K |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (7.6M) | (9.0M) | (13.9M) | (24.2M) | (28.2M) |
| Income Tax Expense | — | — | — | — | (534.0K) |
| Bottom Line | |||||
| Net Income | (7.6M) | (9.0M) | (13.9M) | (24.2M) | (27.6M) |
| Earnings from Cont. Ops | (7.6M) | (9.0M) | (13.9M) | (24.2M) | (27.6M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (7.6M) | (9.0M) | (13.9M) | (24.2M) | (27.6M) |
| Per Share | |||||
| Basic EPS | ($1.02) | ($1.42) | ($68.80) | ($8.22) | ($9.68) |
| Diluted EPS | ($1.02) | ($1.42) | ($68.80) | ($8.22) | ($9.68) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 8.0M | 6.4M | 202906 | 2.9M | 2.8M |
| Diluted Shares Outstanding | 8.0M | 6.4M | 202906 | 2.9M | 2.8M |
| Profitability Metrics | |||||
| EBITDA | (7.9M) | (9.5M) | (14.7M) | (25.4M) | (28.5M) |
| D&A | 41.1K | 70.0K | 53.0K | 67.0K | 57.8K |
| EBIT | (8.0M) | (9.6M) | (14.7M) | (25.5M) | (28.5M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026